Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
about
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitnessThree main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimensHIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravirCharacteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions.Antiretroviral drug resistance in human immunodeficiency virus type 2.Drug resistance in HIV-1.Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance
P2860
Q30494064-0DD679AF-9F62-4050-9A40-51310A63DD98Q33963958-7F601F60-651F-4E63-9E27-146B43F7C5A1Q34148077-F404B2FB-0D68-4A16-97D9-DFE60D264F7AQ34428902-7E643603-AAB1-49F4-9385-6D8C08F12E11Q34520239-FDB0CCA7-5457-408E-9005-FE853FC54430Q34737268-064E89FD-080D-481D-86A0-8567B6BEA87BQ34793224-B880A18D-71FD-48C0-A26D-F989BF6EF4D2Q35083423-78231661-0CB6-47F8-8A47-23A7DBF1EE50Q35134947-290D3C1E-6CC4-4294-BA43-4E1D84D4D17BQ35206272-EDD13F4B-57E2-4F86-BF08-2D252157607FQ36228871-1416B286-8132-4169-9835-A6023208E4AFQ36290647-F7F94DF5-7D59-4BB7-AE6E-FB9373FF74FDQ36839676-B90B538D-F7E3-411E-BA23-640779F51476Q37457791-F168CB0F-2A2A-4791-9B9D-9368E2A5487FQ37496287-BF79223B-6B50-4036-BB72-97572123CF2FQ37967710-553A83AE-D780-4C17-8482-E41D07748CF9Q37979697-ACAE2398-29E0-4FA2-8348-74A45ED88E1EQ58391480-4067C149-A865-4BF1-8374-8F034A281B13
P2860
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Selection of the Q148R integra ...... altegravir containing regimen.
@en
Selection of the Q148R integra ...... altegravir containing regimen.
@nl
type
label
Selection of the Q148R integra ...... altegravir containing regimen.
@en
Selection of the Q148R integra ...... altegravir containing regimen.
@nl
prefLabel
Selection of the Q148R integra ...... altegravir containing regimen.
@en
Selection of the Q148R integra ...... altegravir containing regimen.
@nl
P2093
P50
P1433
P1476
Selection of the Q148R integra ...... altegravir containing regimen.
@en
P2093
ANRS HIV-2 Co5 Cohort
Bénédicte Roquebert
Gilles Collin
Juliette Leleu
Laurent Blum
P304
P356
10.1097/QAD.0B013E32830F4C7D
P407
P577
2008-10-01T00:00:00Z